Tricks with tetramers: how to get the most from multimeric peptide-MHC

Immunology

Volumn 126, Issue 2, 2009, Pages 147-164

  Wooldridge, Linda ^a   Lissina, Anna ^a   Cole, David K ^a   Van Den Berg, Hugo A ^b   Price, David A ^a   Sewell, Andrew K ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Antigen; Flow cytometry; Peptide MHC; T cell; TCR; Tetramer

Indexed keywords

AVIDIN; BIOTIN; CD4 ANTIGEN; DIMER; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYMER; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TETRAMER;

CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; STAINING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TEMPERATURE;

AUTOANTIGENS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; STAINING AND LABELING; T-LYMPHOCYTE SUBSETS;

EID: 58149291771     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02848.x     Document Type: Review

References (117)

1. Laugel B, Boulter JM, Lissin N et al. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J Biol Chem 2005 280 : 1882 92.
2. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996 274 : 94 6.
3. Wooldridge L, van den Berg HA, Glick M et al. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 2005 280 : 27491 501.
4. Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF. Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 2003 278 : 4500 9.
5. Bakker AH, Schumacher TN. MHC multimer technology: current status and future prospects. Curr Opin Immunol 2005 17 : 428 33.
6. Schamel WW, Arechaga I, Risueno RM, van Santen HM, Cabezas P, Risco C, Valpuesta JM, Alarcon B. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005 202 : 493 503.
7. Whelan JA, Dunbar PR, Price DA et al. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J Immunol 1999 163 : 4342 8.
8. Dal Porto J, Johansen TE, Catipovic B et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 1993 90 : 6671 5.
9. Greten TF, Slansky JE, Kubota R et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci USA 1998 95 : 7568 73.
10. Laugel B, van den Berg HA, Gostick E et al. Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties. J Biol Chem 2007 282 : 23799 810.
11. Purbhoo MA, Li Y, Sutton DH et al. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 2007 6 : 2081 91.
12. Cole DK, Pumphrey NJ, Boulter JM et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol 2007 178 : 5727 34.
13. Falta MT, Fontenot AP, Rosloniec EF et al. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum 2005 52 : 1885 96.
14. Gebe JA, Falk BA, Rock KA, Kochik SA, Heninger AK, Reijonen H, Kwok WW, Nepom GT. Low-avidity recognition by CD4+ T cells directed to self-antigens. Eur J Immunol 2003 33 : 1409 17.
15. Rubio-Godoy V, Dutoit V, Rimoldi D et al. Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA 2001 98 : 10302 7.
16. Lyons GE, Roszkowski JJ, Man S, Kast WM, Nishimura MI. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2006 55 : 1142 50.
17. Weichsel R, Dix C, Wooldridge L et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008 14 : 2484 91.
18. Lissina A, Ladell K, Skowera A et al. Protein kinase inhibitors substantially improve the physical detection of T cells with peptide-MHC tetramers. J Immunol Methods 2008 (in press).
19. Wooldridge L, Hutchinson SL, Choi EM et al. Anti-CD8 antibodies can inhibit or enhance peptide-MHC class I (pMHCI) multimer binding: this is paralleled by their effects on CTL activation and occurs in the absence of an interaction between pMHCI and CD8 on the cell surface. J Immunol 2003 171 : 6650 60.
20. Wooldridge L, Scriba TJ, Milicic A, Laugel B, Gostick E, Price DA, Phillips RE, Sewell AK. Anti-coreceptor antibodies profoundly affect staining with peptide-MHC class I and class II tetramers. Eur J Immunol 2006 36 : 1847 55.
21. Daniels MA, Jameson SC. Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimers. J Exp Med 2000 191 : 335 46.
22. Chattopadhyay PK, Price DA, Harper TF et al. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med 2006 12 : 972 7.
23. Barnes E, Ward SM, Kasprowicz VO, Dusheiko G, Klenerman P, Lucas M. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur J Immunol 2004 34 : 1570 7.
24. Oxenius A, Sewell AK, Dawson SJ et al. Functional discrepancies in HIV-specific CD8+ T-lymphocyte populations are related to plasma virus load. J Clin Immunol 2002 22 : 363 74.
25. Alexander-Miller MA. Differential expansion and survival of high and low avidity cytotoxic T cell populations during the immune response to a viral infection. Cell Immunol 2000 201 : 58 62.
26. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996 93 : 4102 7.
27. Dutoit V, Rubio-Godoy V, Doucey MA et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J Immunol 2002 168 : 1167 71.
28. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998 187 : 1647 57.
29. Messaoudi I, Guevara Patino JA, Dyall R, LeMaoult J, Nikolich-Zugich J. Direct link between MHC polymorphism, T-cell avidity, and diversity in immune defense. Science 2002 298 : 1797 800.
30. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, Casal SI, Leclerc C. In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 2000 74 : 5769 75.
31. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999 162 : 2227 34.
32. Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003 111 : 639 47.
33. Zeh HJ 3rd., Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999 162 : 989 94.
34. McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A 1995 92 : 5042 6.
35. Kroger CJ, Alexander-Miller MA. Cutting edge: CD8+ T cell clones possess the potential to differentiate into both high- and low-avidity effector cells. J Immunol 2007 179 : 748 51.
36. Arcaro A, Gregoire C, Bakker TR et al. CD8β endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. J Exp Med 2001 194 : 1485 95.
37. Huang J, Edwards LJ, Evavold BD, Zhu C. Kinetics of MHC-CD8 interaction at the T cell membrane. J Immunol 2007 179 : 7653 62.
38. Kwan-Lim GE, Ong T, Aosai F, Stauss H, Zamoyska R. Is CD8 dependence a true reflection of TCR affinity for antigen? Int Immunol 1993 5 : 1219 28.
39. Cawthon AG, Lu H, Alexander-Miller MA. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J Immunol 2001 167 : 2577 84.
40. Gao GF, Tormo J, Gerth UC et al. Crystal structure of the complex between human CD8α(α) and HLA-A2. Nature 1997 387 : 630 4.
41. Wang JH, Meijers R, Xiong Y, Liu JH, Sakihama T, Zhang R, Joachimiak A, Reinherz EL. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci U S A 2001 98 : 10799 804.
42. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003 18 : 255 64.
43. Janeway CA Jr. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 1992 10 : 645 74.
44. Laugel B, Price DA, Milicic A, Sewell AK. CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions. Eur J Immunol 2007 37 : 905 13.
45. Park JH, Adoro S, Lucas PJ et al. 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol 2007 8 : 1049 59.
46. Glaichenhaus N, Shastri N, Littman DR, Turner JM. Requirement for association of p56lck with CD4 in antigen-specific signal transduction in T cells. Cell 1991 64 : 511 20.
47. Purbhoo MA, Boulter JM, Price DA et al. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001 276 : 32786 92.
48. Veillette A, Bookman MA, Horak EM, Bolen JB. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 1988 55 : 301 8.
49. Bosselut R, Zhang W, Ashe JM, Kopacz JL, Samelson LE, Singer A. Association of the adaptor molecule LAT with CD4 and CD8 coreceptors identifies a new coreceptor function in T-cell receptor signal transduction. J Exp Med 1999 190 : 1517 26.
50. Gakamsky DM, Luescher IF, Pramanik A, Kopito RB, Lemonnier F, Vogel H, Rigler R, Pecht I. CD8 kinetically promotes ligand binding to the T-cell antigen receptor. Biophys J 2005 89 : 2121 33.
51. Dianzani U, Shaw A, al-Ramadi BK, Kubo RT, Janeway CA Jr. Physical association of CD4 with the T cell receptor. J Immunol 1992 148 : 678 88.
52. Doucey MA, Goffin L, Naeher D, Michielin O, Baumgartner P, Guillaume P, Palmer E, Luescher IF. CD3 delta establishes a functional link between the T cell receptor and CD8. J Biol Chem 2003 278 : 3257 64.
53. Kwan Lim GE, McNeill L, Whitley K, Becker DL, Zamoyska R. Co-capping studies reveal CD8/TCR interactions after capping CD8 beta polypeptides and intracellular associations of CD8 with p56(lck). Eur J Immunol 1998 28 : 745 54.
54. Naeher D, Luescher IF, Palmer E. A role for the alpha-chain connecting peptide motif in mediating TCR-CD8 cooperation. J Immunol 2002 169 : 2964 70.
55. Suzuki S, Kupsch J, Eichmann K, Saizawa MK. Biochemical evidence of the physical association of the majority of CD3 delta chains with the accessory/co-receptor molecules CD4 and CD8 on nonactivated T lymphocytes. Eur J Immunol 1992 22 : 2475 9.
56. Demotte N, Stroobant V, Courtoy PJ, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008 28 : 414 24.
57. Wyer JR, Willcox BE, Gao GF, Gerth UC, Davis SJ, Bell JI, van der Merwe PA, Jakobsen BK. T cell receptor and coreceptor CD8 αα bind peptide-MHC independently and with distinct kinetics. Immunity 1999 10 : 219 25.
58. Cole DK, Dunn SM, Sami M, Boulter JM, Sewell AK, Jakobsen BK. Co-engagement of the CD8αα co-receptor to peptide-major histocompatibility complexes: the effect of T-cell receptor docking on CD8 binding. Mol Immunol 2008 45 : 2700 9.
59. van den Berg HA, Wooldridge L, Laugel B, Sewell AK. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J Theor Biol 2007 249 : 395 408.
60. Maile R, Siler CA, Kerry SE, Midkiff KE, Collins EJ, Frelinger JA. Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol 2005 174 : 619 27.
61. Kroger CJ, Alexander-Miller MA. Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter. Immunology 2007 122 : 167 78.
62. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007 13 : 1440 9.
63. Plas DR, Thomas ML. Negative regulation of antigen receptor signaling in lymphocytes. J Mol Med 1998 76 : 589 95.
64. Johnson KG, LeRoy FG, Borysiewicz LK, Matthews RJ. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J Immunol 1999 162 : 3802 13.
65. Sathish JG, Dolton G, Leroy FG, Matthews RJ. Loss of Src homology region 2 domain-containing protein tyrosine phosphatase-1 increases CD8+ T cell-APC conjugate formation and is associated with enhanced in vivo CTL function. J Immunol 2007 178 : 330 7.
66. Derby M, Alexander-Miller M, Tse R, Berzofsky J. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 2001 166 : 1690 7.
67. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996 184 : 485 92.
68. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ. Maintenance, loss, and resurgence of T cell responses during acute, protracted, and chronic viral infections. J Immunol 2004 172 : 4204 14.
69. Fuller MJ, Zajac AJ. Ablation of CD8 and CD4 T cell responses by high viral loads. J Immunol 2003 170 : 477 86.
70. Gallimore A, Glithero A, Godkin A, Tissot AC, Pluckthun A, Elliott T, Hengartner H, Zinkernagel R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998 187 : 1383 93.
71. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000 191 : 1499 512.
72. Moskophidis D, Laine E, Zinkernagel RM. Peripheral clonal deletion of antiviral memory CD8+ T cells. Eur J Immunol 1993 23 : 3306 11.
73. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993 362 : 758 61.
74. Xiong Y, Luscher MA, Altman JD, Hulsey M, Robinson HL, Ostrowski M, Barber BH, MacDonald KS. Simian immunodeficiency virus (SIV) infection of a rhesus macaque induces SIV-specific CD8(+) T cells with a defect in effector function that is reversible on extended interleukin-2 incubation. J Virol 2001 75 : 3028 33.
75. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998 188 : 2205 13.
76. Choi EM, Chen JL, Wooldridge L et al. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J Immunol 2003 171 : 5116 23.
77. Hutchinson SL, Wooldridge L, Tafuro S et al. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J Biol Chem 2003 278 : 24285 93.
78. Schott E, Bertho N, Ge Q, Maurice MM, Ploegh HL. Class I negative CD8 T cells reveal the confounding role of peptide-transfer onto CD8 T cells stimulated with soluble H2-Kb molecules. Proc Natl Acad Sci USA 2002 99 : 13735 40.
79. Schott E, Ploegh HL. Mouse MHC class I tetramers that are unable to bind to CD8 reveal the need for CD8 engagement in order to activate naive CD8 T cells. Eur J Immunol 2002 32 : 3425 34.
80. Pittet MJ, Rubio-Godoy V, Bioley G et al. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 2003 171 : 1844 9.
81. Wooldridge L, Lissina A, Vernazza J et al. Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol 2007 37 : 1323 33.
82. Melenhorst JJ, Scheinberg P, Lissina A et al. Detection of low avidity CD8+ T cells with coreceptor-enhanced peptide-MHC class I tetramers. J Immunol Methods 2008 338 : 3390 402.
83. Kasprowicz V, Ward SM, Turner A et al. Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J Clin Invest 2008 118 : 1143 53.
84. Douek DC, Betts MR, Brenchley JM et al. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol 2002 168 : 3099 104.
85. Price DA, Sewell AK. Quantitative clonotypic analysis of antigen-specific T-cell responses. Trends Immunol 2002 23 : 336 7.
86. Price DA, West SM, Betts MR et al. T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity 2004 21 : 793 803.
87. Price DA, Brenchley JM, Ruff LE et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med 2005 202 : 1349 61.
88. Davenport MP, Price DA, McMichael AJ. The T cell repertoire in infection and vaccination: implications for control of persistent viruses. Curr Opin Immunol 2007 19 : 294 300.
89. Gras S, Kjer-Nielsen L, Burrows SR, McCluskey J, Rossjohn J. T-cell receptor bias and immunity. Curr Opin Immunol 2008 20 : 119 25.
90. Dunbar PR, Chen JL, Chao D et al. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol 1999 162 : 6959 62.
91. Cebecauer M, Guillaume P, Hozak P, Mark S, Everett H, Schneider P, Luescher IF. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J Immunol 2005 174 : 6809 19.
92. Xu XN, Purbhoo MA, Chen N et al. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 2001 14 : 591 602.
93. Guillaume P, Baumgaertner P, Angelov GS, Speiser D, Luescher IF. Fluorescence-activated cell sorting and cloning of bona fide CD8+ CTL with reversible MHC-peptide and antibody Fab′ conjugates. J Immunol 2006 177 : 3903 12.
94. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003 281 : 65 78.
95. Moris A, Teichgraber V, Gauthier L, Buhring HJ, Rammensee HG. Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 2001 166 : 4818 21.
96. Whitelegg AM, Oosten LE, Jordan S, Kester M, van Halteren AG, Madrigal JA, Goulmy E, Barber LD. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J Immunol 2005 175 : 1706 14.
97. Kappel BJ, Pinilla-Ibarz J, Kochman AA et al. Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. Blood 2006 107 : 2045 51.
98. Massey RC, Scriba TJ, Brown EL, Phillips RE, Sewell AK. Use of peptide-major histocompatibility complex tetramer technology to study interactions between Staphylococcus aureus proteins and human cells. Infect Immun 2007 75 : 5711 5.
99. Delon J, Gregoire C, Malissen B, Darche S, Lemaitre F, Kourilsky P, Abastado JP, Trautmann A. CD8 expression allows T cell signaling by monomeric peptide-MHC complexes. Immunity 1998 9 : 467 73.
100. Ge Q, Stone JD, Thompson MT, Cochran JR, Rushe M, Eisen HN, Chen J, Stern LJ. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules. Proc Natl Acad Sci USA 2002 99 : 13729 34.
101. Davis SJ, van der Merwe PA. The structure and ligand interactions of CD2: implications for T-cell function. Immunol Today 1996 17 : 177 87.
102. Choudhuri K, Wiseman D, Brown MH, Gould K, van der Merwe PA. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature 2005 436 : 578 82.
103. Casares S, Hurtado A, McEvoy RC, Sarukhan A, von Boehmer H, Brumeanu TD. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat Immunol 2002 3 : 383 91.
104. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA. Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes. J Immunol 2003 171 : 5587 95.
105. Zuo L, Cullen CM, DeLay ML, Thornton S, Myers LK, Rosloniec EF, Boivin GP, Hirsch R. A single-chain class II MHC-IgG3 fusion protein inhibits autoimmune arthritis by induction of antigen-specific hyporesponsiveness. J Immunol 2002 168 : 2554 9.
106. Sakita I, Horig H, Sun R, Wang F, Nathenson SG. In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex. J Immunol Methods 1996 192 : 105 15.
107. Maile R, Wang B, Schooler W, Meyer A, Collins EJ, Frelinger JA. Antigen-specific modulation of an immune response by in vivo administration of soluble MHC class I tetramers. J Immunol 2001 167 : 3708 14.
108. Yuan RR, Wong P, McDevitt MR et al. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood 2004 104 : 2397 402.
109. Hess PR, Barnes C, Woolard MD, Johnson MD, Cullen JM, Collins EJ, Frelinger JA. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 2007 109 : 3300 7.
110. Boniface JJ, Rabinowitz JD, Wulfing C et al. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. Immunity 1998 9 : 459 66.
111. Crawford F, Kozono H, White J, Marrack P, Kappler J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 1998 8 : 675 82.
112. Hamad AR, O'Herrin SM, Lebowitz MS, Srikrishnan A, Bieler J, Schneck J, Pardoll D. Potent T cell activation with dimeric peptide-major histocompatibility complex class II ligand: the role of CD4 coreceptor. J Exp Med 1998 188 : 1633 40.
113. Scriba TJ, Purbhoo M, Day CL et al. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol 2005 175 : 6334 43.
114. Vollers SS, Stern LJ. Class II major histocompatibility complex tetramer staining: progress, problems and prospects. Immunology 2008 123 : 305 13.
115. Varela-Rohena A, Molloy PE, Dunn SM, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 2008 (in press)
116. Sewell AK, Harcourt GC, Goulder PJ, Price DA, Phillips RE. Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides. Eur J Immunol 1997 27 : 2323 9.
117. Green AE, Lissina A, Hutchinson SL et al. Recognition of nonpeptide antigens by human Vγ9Vδ2 T cells requires contact with cells of human origin. Clin Exp Immunol 2004 136 : 472 82.